{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:43:35Z","timestamp":1776440615192,"version":"3.51.2"},"reference-count":14,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.clinthera.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T17:20:57Z","timestamp":1596820857000},"page":"1840-1845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dabigatran Reversal With Idarucizumab Preceding Thrombolysis in an Octogenarian Patient with Chronic Kidney Disease and Acute Stroke: A Case Report"],"prefix":"10.1016","volume":"42","author":[{"given":"Lina C.","family":"Laxamana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Oliver C.","family":"Co","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeryl Ritzi T.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-1480","authenticated-orcid":false,"given":"Christianne V.","family":"Mojica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Adelaida M.","family":"Iboleon-Dy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa Mae C.","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Czarina S.","family":"Ilano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5559-5246","authenticated-orcid":false,"given":"Ma Cristina Z.","family":"Macrohon-Valdez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.07.006_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40268-019-0274-z","article-title":"Comparison of the new oral anticoagulants and warfarin in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis","volume":"19","author":"de Souza Lima Bitar","year":"2019","journal-title":"Drugs R D"},{"key":"10.1016\/j.clinthera.2020.07.006_bib2","article-title":"Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation","volume":"7","author":"Chan","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2020.07.006_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/rth2.12089","article-title":"Pharmacological reversal of the direct oral anticoagulants\u2014a comprehensive review of the literature","volume":"2","author":"Shaw","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.clinthera.2020.07.006_bib4","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A\u00a0specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2020.07.006_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH16-05-0385","article-title":"Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers","volume":"117","author":"Schmohl","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2020.07.006_bib6","first-page":"321","article-title":"Consensus guides on stroke thrombolysis for anticoagulated patients from Japan: application to other populations","volume":"20","author":"Toyoda","year":"2018","journal-title":"J\u00a0Stroke"},{"key":"10.1016\/j.clinthera.2020.07.006_bib7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13760-017-0751-5","article-title":"Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer","volume":"117","author":"Turine","year":"2017","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.clinthera.2020.07.006_bib8","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1212\/WNL.0b013e3182697e70","article-title":"Blood-brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke","volume":"79","author":"Khatri","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2020.07.006_bib9","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1161\/STROKEAHA.110.586438","article-title":"Outcomes of thrombolysis for acute ischemic stroke in octogenarians versus nonagenarians","volume":"41","author":"Mateen","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2020.07.006_bib10","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/CIRCULATIONAHA.116.023940","article-title":"Use of intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke who take non\u2013vitamin K antagonist oral anticoagulants before stroke","volume":"135","author":"Xian","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2020.07.006_bib11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40263-017-0460-x","article-title":"Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving alteplase: a systematic review of the available evidence","volume":"31","author":"Pikija","year":"2017","journal-title":"CNS drugs"},{"key":"10.1016\/j.clinthera.2020.07.006_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1747493019895654","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany\u2014updated series of 120 cases","author":"Kermer","year":"2020","journal-title":"Int J Stroke"},{"key":"10.1016\/j.clinthera.2020.07.006_bib13","first-page":"692","article-title":"Evidence for idarucizumab (Praxbind) in the reversal of the direct thrombin inhibitor dabigatran: review following the RE- VERSE AD full cohort analysis","volume":"42","author":"Hutcherson","year":"2017","journal-title":"P\u00a0T"},{"key":"10.1016\/j.clinthera.2020.07.006_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.01644","article-title":"A\u00a0renal function based trade-off analysis of non-vitamin K antagonist oral anticoagulants in nonvalvular atrial fibrillation","volume":"9","author":"Zhou","year":"2018","journal-title":"Front Physiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820303404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820303404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:53:03Z","timestamp":1758963183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820303404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0149291820303404"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.07.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dabigatran Reversal With Idarucizumab Preceding Thrombolysis in an Octogenarian Patient with Chronic Kidney Disease and Acute Stroke: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}